Experts criticise new German law for favouring drug companies
BMJ 2010; 341 doi: https://doi.org/10.1136/bmj.c5650 (Published 13 October 2010) Cite this as: BMJ 2010;341:c5650- Annette Tuffs
- 1Heidelberg
A new law on approving drugs for reimbursement by German insurance companies currently being debated in parliament could put the safety of patients at risk, experts have warned.
The law would substantially weaken the role of the German Institute for Quality and Efficiency in Health Care (IQWiG), the German equivalent of the UK National Institute for Health and Clinical Excellence, and lead to inefficient and dangerous drugs being approved, say experts.
An amendment to the law proposed by the governing coalition of the Christian Democrats and the liberal Free Democratic Party says that all new …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £184 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£50 / $60/ €56 (excludes VAT)
You can download a PDF version for your personal record.